MEDI-545: Clinical Trials

3 trials of MEDI-545, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow MEDI-545: new trials by email Literature Review of MEDI-545 trials Research Report on MEDI-545

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Sifalimumab 200 mg, Sifalimumab 600 mg, Sifalimumab 1,200 mg - Systemic Lupus Erythematosus
Phase 2CompletedMedImmune LLC8342011-03-312018-04-19
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
MEDI-545, MEDI-545 600 - Systemic Lupus Erythematosus
Phase 2CompletedAstraZeneca302009-11-252018-11-19
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
MEDI-545, Placebo - Lupus Erythematosus, Systemic, Lupus
Phase 2CompletedMedImmune LLC872008-07-012016-08-09

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Autoimmune Diseases (1)  ·  Immune System Diseases (1)

Sponsors

MedImmune LLC (2)  ·  AstraZeneca (1)

Countries

United States (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Chile (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)  ·  Jamaica (1)  ·  Japan (1)  ·  Mexico (1)  ·  Netherlands (1)

Top investigators

Gabor Illei, MD (1)  ·  Tsutomu Takeuchi (1)  ·  Warren Greth, M.D. (1)  ·  Yoshiya Tanaka (1)

Results publications

PMID 21798883, PMID 31660791, PMID 33687069